The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
The global Biosimilars Insulin market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Biosimilars Insulin in various end use industries. The expanding demands from the Type I Diabetes and Type II Diabetes, are propelling Biosimilars Insulin market. Insulin Glargine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Insulin Aspart segment is estimated at % CAGR for the next seven-year period.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biosimilars Insulin, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biosimilars Insulin market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biosimilars Insulin market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biosimilars Insulin sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biosimilars Insulin covered in this report include Eli Lilly, Boehringer Ingelheim, Biocon/Mylan, Gan & Lee Pharmaceuticals, Tonghua Dongbao, United Laboratories and Sanofi, etc.
The global Biosimilars Insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
- Eli Lilly
- Boehringer Ingelheim
- Biocon/Mylan
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao
- United Laboratories
- Sanofi
Global Biosimilars Insulin market, by region:
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, UK, Italy, etc.)
- Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
- South America (Brazil, etc.)
- Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biosimilars Insulin market, Segment by Type:
- Insulin Glargine
- Insulin Aspart
- Insulin Lispro
- Other
Global Biosimilars Insulin market, by Application
- Type I Diabetes
- Type II Diabetes
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Biosimilars Insulin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Biosimilars Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Biosimilars Insulin Market Overview
1.1 Biosimilars Insulin Product Overview
1.2 Biosimilars Insulin Market Segment by Type
1.2.1 Insulin Glargine
1.2.2 Insulin Aspart
1.2.3 Insulin Lispro
1.2.4 Other
1.3 Global Biosimilars Insulin Market Size by Type
1.3.1 Global Biosimilars Insulin Market Size Overview by Type (2018-2029)
1.3.2 Global Biosimilars Insulin Historic Market Size Review by Type (2018-2023)
1.3.3 Global Biosimilars Insulin Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Biosimilars Insulin Sales Breakdown by Type (2018-2023)
1.4.2 Europe Biosimilars Insulin Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Biosimilars Insulin Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Biosimilars Insulin Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Biosimilars Insulin Sales Breakdown by Type (2018-2023)
2 Global Biosimilars Insulin Market Competition by Company
2.1 Global Top Players by Biosimilars Insulin Sales (2018-2023)
2.2 Global Top Players by Biosimilars Insulin Revenue (2018-2023)
2.3 Global Top Players by Biosimilars Insulin Price (2018-2023)
2.4 Global Top Manufacturers Biosimilars Insulin Manufacturing Base Distribution, Sales Area, Product Type
2.5 Biosimilars Insulin Market Competitive Situation and Trends
2.5.1 Biosimilars Insulin Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Biosimilars Insulin Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biosimilars Insulin as of 2022)
2.7 Date of Key Manufacturers Enter into Biosimilars Insulin Market
2.8 Key Manufacturers Biosimilars Insulin Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Biosimilars Insulin Status and Outlook by Region
3.1 Global Biosimilars Insulin Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Biosimilars Insulin Historic Market Size by Region
3.2.1 Global Biosimilars Insulin Sales in Volume by Region (2018-2023)
3.2.2 Global Biosimilars Insulin Sales in Value by Region (2018-2023)
3.2.3 Global Biosimilars Insulin Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Biosimilars Insulin Forecasted Market Size by Region
3.3.1 Global Biosimilars Insulin Sales in Volume by Region (2024-2029)
3.3.2 Global Biosimilars Insulin Sales in Value by Region (2024-2029)
3.3.3 Global Biosimilars Insulin Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Biosimilars Insulin by Application
4.1 Biosimilars Insulin Market Segment by Application
4.1.1 Type I Diabetes
4.1.2 Type II Diabetes
4.2 Global Biosimilars Insulin Market Size by Application
4.2.1 Global Biosimilars Insulin Market Size Overview by Application (2018-2029)
4.2.2 Global Biosimilars Insulin Historic Market Size Review by Application (2018-2023)
4.2.3 Global Biosimilars Insulin Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Biosimilars Insulin Sales Breakdown by Application (2018-2023)
4.3.2 Europe Biosimilars Insulin Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Biosimilars Insulin Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Biosimilars Insulin Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Biosimilars Insulin Sales Breakdown by Application (2018-2023)
5 North America Biosimilars Insulin by Country
5.1 North America Biosimilars Insulin Historic Market Size by Country
5.1.1 North America Biosimilars Insulin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Biosimilars Insulin Sales in Volume by Country (2018-2023)
5.1.3 North America Biosimilars Insulin Sales in Value by Country (2018-2023)
5.2 North America Biosimilars Insulin Forecasted Market Size by Country
5.2.1 North America Biosimilars Insulin Sales in Volume by Country (2024-2029)
5.2.2 North America Biosimilars Insulin Sales in Value by Country (2024-2029)
6 Europe Biosimilars Insulin by Country
6.1 Europe Biosimilars Insulin Historic Market Size by Country
6.1.1 Europe Biosimilars Insulin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Biosimilars Insulin Sales in Volume by Country (2018-2023)
6.1.3 Europe Biosimilars Insulin Sales in Value by Country (2018-2023)
6.2 Europe Biosimilars Insulin Forecasted Market Size by Country
6.2.1 Europe Biosimilars Insulin Sales in Volume by Country (2024-2029)
6.2.2 Europe Biosimilars Insulin Sales in Value by Country (2024-2029)
7 Asia-Pacific Biosimilars Insulin by Region
7.1 Asia-Pacific Biosimilars Insulin Historic Market Size by Region
7.1.1 Asia-Pacific Biosimilars Insulin Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Biosimilars Insulin Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Biosimilars Insulin Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Biosimilars Insulin Forecasted Market Size by Region
7.2.1 Asia-Pacific Biosimilars Insulin Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Biosimilars Insulin Sales in Value by Region (2024-2029)
8 Latin America Biosimilars Insulin by Country
8.1 Latin America Biosimilars Insulin Historic Market Size by Country
8.1.1 Latin America Biosimilars Insulin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Biosimilars Insulin Sales in Volume by Country (2018-2023)
8.1.3 Latin America Biosimilars Insulin Sales in Value by Country (2018-2023)
8.2 Latin America Biosimilars Insulin Forecasted Market Size by Country
8.2.1 Latin America Biosimilars Insulin Sales in Volume by Country (2024-2029)
8.2.2 Latin America Biosimilars Insulin Sales in Value by Country (2024-2029)
9 Middle East and Africa Biosimilars Insulin by Country
9.1 Middle East and Africa Biosimilars Insulin Historic Market Size by Country
9.1.1 Middle East and Africa Biosimilars Insulin Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Biosimilars Insulin Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Biosimilars Insulin Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Biosimilars Insulin Forecasted Market Size by Country
9.2.1 Middle East and Africa Biosimilars Insulin Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Biosimilars Insulin Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Eli Lilly
10.1.1 Eli Lilly Company Information
10.1.2 Eli Lilly Introduction and Business Overview
10.1.3 Eli Lilly Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Eli Lilly Biosimilars Insulin Products Offered
10.1.5 Eli Lilly Recent Development
10.2 Boehringer Ingelheim
10.2.1 Boehringer Ingelheim Company Information
10.2.2 Boehringer Ingelheim Introduction and Business Overview
10.2.3 Boehringer Ingelheim Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Boehringer Ingelheim Biosimilars Insulin Products Offered
10.2.5 Boehringer Ingelheim Recent Development
10.3 Biocon/Mylan
10.3.1 Biocon/Mylan Company Information
10.3.2 Biocon/Mylan Introduction and Business Overview
10.3.3 Biocon/Mylan Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Biocon/Mylan Biosimilars Insulin Products Offered
10.3.5 Biocon/Mylan Recent Development
10.4 Gan & Lee Pharmaceuticals
10.4.1 Gan & Lee Pharmaceuticals Company Information
10.4.2 Gan & Lee Pharmaceuticals Introduction and Business Overview
10.4.3 Gan & Lee Pharmaceuticals Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Gan & Lee Pharmaceuticals Biosimilars Insulin Products Offered
10.4.5 Gan & Lee Pharmaceuticals Recent Development
10.5 Tonghua Dongbao
10.5.1 Tonghua Dongbao Company Information
10.5.2 Tonghua Dongbao Introduction and Business Overview
10.5.3 Tonghua Dongbao Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Tonghua Dongbao Biosimilars Insulin Products Offered
10.5.5 Tonghua Dongbao Recent Development
10.6 United Laboratories
10.6.1 United Laboratories Company Information
10.6.2 United Laboratories Introduction and Business Overview
10.6.3 United Laboratories Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
10.6.4 United Laboratories Biosimilars Insulin Products Offered
10.6.5 United Laboratories Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Information
10.7.2 Sanofi Introduction and Business Overview
10.7.3 Sanofi Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Sanofi Biosimilars Insulin Products Offered
10.7.5 Sanofi Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Biosimilars Insulin Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Biosimilars Insulin Industrial Chain Analysis
11.4 Biosimilars Insulin Market Dynamics
11.4.1 Biosimilars Insulin Industry Trends
11.4.2 Biosimilars Insulin Market Drivers
11.4.3 Biosimilars Insulin Market Challenges
11.4.4 Biosimilars Insulin Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Biosimilars Insulin Distributors
12.3 Biosimilars Insulin Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
